Company intelligence / Profile preview

Motek Pharmaceuticals

Jerusalem, Israel

Ownership: Private
Development stage: Other

Overview

Motek Pharmaceuticals is an Israeli biotechnology company that specialized in the development of peptide-based therapeutics for autoimmune and inflammatory diseases. The company's lead program, MTK-001, was designed to target the CD44v6 isoform to inhibit the migration of pro-inflammatory cells into affected tissues. Based on research from the Hebrew University of Jerusalem, the company aimed to treat conditions such as rheumatoid arthritis and Crohn's disease. While the company reached early clinical stages, it has not shown significant operational activity in recent years.

Therapeutic areas: ImmunologyNeurologyGastroenterology
Modalities: Peptides
Industry: Biotech

Beyond the preview

Go deeper on Motek Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Motek Pharmaceuticals.

Explore the full profile